According to the research report titled ‘Europe Cardiac Ablation Market Forecast 2028 By Application, By Product Ablators, By Approach, By End-use, Research Report, Country Outlook, COVID-19 Impact Statistics, Country Outlook, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with MarketStudyReport, Europe cardiac ablation market is anticipated to amass a valuation of USD 2.5 billion by the year 2028.

Rising prevalence of cardiovascular diseases has resulted in an increase in the number of therapeutic procedures, which along with growing focus among players to satisfy the requirements of rising patient pool and reduce death rate are the major growth stimulants for Europe cardiac ablation market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4966040/  

Growing geriatric population, combined with customer preference for fast-food meals and poor lifestyle patterns is anticipated to intensify the sickness burden, which in turn is expected to augment industry outlook during the forecast period.

However, high risk associated with cardiac ablation operations, as well as the current regulatory environment could stymie the market's growth prospects.

In terms of approach, the market is bifurcated into open/surgical, and catheter based. On the basis of application, the marketplace is classified into tachycardia, atrial fibrillation, and others.

Based on product terrain, the industry is branched into ultrasound ablators, cryoablation devices, electric ablators, radiofrequency ablators, and others. Among these, radiofrequency ablators segment was worth USD 580 million in 2021, due to benefits of procedure such as cost-effectiveness, enhanced availability, and rapid relief.

Speaking of end-user scope, Europe cardiac ablation market is categorized into cardiac centers, ambulatory surgical centers, hospitals, and others. Among these, hospitals segment held 60% revenue share in 2021, owing to the ability of this setting to serve large number of patients.

Regionally, U.K. industry is slated to record 14.4% CAGR through 2028, due to growing cognizance of the benefits of minimally invasive therapies and rising healthcare expenditure in the country.

Whereas Germany market accounted for 20% revenue share in 2021, because of the increasing risk of cardiac arrhythmias and other heart diseases among the ever-increasing elderly population in the country.

Olympus Corporation, Smith & Nephew plc, Stereotaxis, Inc., MicroPort Scientific Corporation, Medtronic plc, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, Biosense Webster, Inc., AngioDynamics, Inc., and Abbott Laboratories are the leading players in Europe cardiac ablation industry.